These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35924047)

  • 1. Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.
    Ji XW; Zhu X; Li Y; Xue F; Kuan IHS; He QF; Meng XR; Xiang XQ; Cui YM; Zheng B
    Front Pharmacol; 2022; 13():856792. PubMed ID: 35924047
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic analysis of cefoperazone/sulbactam for the treatment of pediatric sepsis by Monte Carlo simulation.
    Ye L; Cheng L; Kong L; Zhao X; Xie G; He J; Liu H; Deng Y; Wu X; Wang T; Yang X
    Anal Methods; 2022 Mar; 14(11):1148-1154. PubMed ID: 35225994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against
    Ji XW; Xue F; Kang ZS; Zhong W; Kuan IH; Yang XP; Zhu X; Li Y; Lv Y
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.
    Chang PC; Chen CC; Lu YC; Lai CC; Huang HL; Chuang YC; Tang HJ
    J Microbiol Immunol Infect; 2018 Apr; 51(2):207-213. PubMed ID: 29037802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms.
    Lai CC; Chen CC; Lu YC; Lin TP; Chuang YC; Tang HJ
    Infect Drug Resist; 2018; 11():1441-1445. PubMed ID: 30237728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment.
    Dong Y; Li Y; Zhang Y; Zhang T; Zhu L; Dong Y; Wang T
    Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):353-359. PubMed ID: 31056857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.
    Ito A; Tatsumi Y; Wajima T; Nakamura R; Tsuji M
    Jpn J Antibiot; 2014 Apr; 67(2):109-22. PubMed ID: 24956910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulating moxalactam dosage for extended-spectrum β-lactamase-producing
    Huang C; Shi Q; Zheng B; Ji J; Ying C; Yu X; Wang H; Xiao Y
    Infect Drug Resist; 2019; 12():1199-1208. PubMed ID: 31190908
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
    Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
    J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation.
    Wang X; Xiong L; Yu W; Huang C; Ji J; Ying C; Liu Z; Chen Y; Xiao Y
    Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1990; 13(1):45-9. PubMed ID: 2331849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of cefoperazone and cefoperazone plus sulbactam in a neutropenic site model.
    Fasching CE; Moody JA; Sinn LM; Tenquist J; Gerding DN; Peterson LR
    Diagn Microbiol Infect Dis; 1991; 14(2):147-55. PubMed ID: 1873973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
    Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN; Barry AL; Thornsberry C; Wilson HW
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The activity of moxalactam against Enterobacteriaceae and anaerobia in vitro].
    Quan JJ; Wang Y; Ji JS; Wang YF; Wang HP; Xu YC; Yu YS
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1459-64. PubMed ID: 27266357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria.
    Lim VK; Halijah MY
    Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
    Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
    J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.